Small Steps and Giant Leaps or Just Getting on With It?

Ian D. Davis MBBS (Hons), PhD, FRACP, FACHPM1,2,3,*

1Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, 2Cancer Services, Eastern Health, Melbourne, Victoria, Australia, and 3Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Sydney, New South Wales, Australia

Correspondence to: Ian D. Davis, MBBS (Hons), PhD, FRACP, FACHPM, Eastern Health Clinical School, Level 2, 5 Arnold St, Box Hill, Victoria 3128, Australia (e-mail: ian.davis@monash.edu).

20 July 1969: People around the world are glued to televisions showing grainy images of Neil Armstrong, poised on the bottom step of the Apollo 11 lunar module, as he utters the immortal words: “That’s probably far enough. We’ve shown we can do it. Let’s go home.”

Research that generates information that could improve the human condition but is not properly tested in clinical trials can be likened to landing on the moon and failing to take the final one small step. Everything that has gone before—all the basic and preclinical work, the grant applications, the dogged endurance—is critical, but in a real sense it is all wasted unless the information is taken into a clinical trial so that we can discover whether outcomes are improved. Imagine how much worse it is to have the evidence and the means to improve outcomes but not to use them.

It is now more than 7 years since the CHAARTED (E3805) data were presented at the annual American Society of Clinical Oncology meeting, showing a striking improvement in overall survival with the addition of docetaxel to testosterone suppression for men with metastatic hormone-sensitive prostate cancer (1). These findings were supported by data from STAMPEDE (2). Soon afterwards, benefits of similar magnitude were observed with abiraterone (3,4), this time with no ambiguity over whether the benefit was restricted to high-volume/high-risk disease. The theme continued, with survival benefits in the same context observed with addition to testosterone suppression of apalutamide (5), enzalutamide (6-8), and again with abiraterone (9,10). Of note, all these benefits are much greater in magnitude than when the same agents are used in the castration-resistant setting. They were not the result of a lack of access to or “stealing” benefit from subsequent life-prolonging therapies. The treatments did not lead to meaningful detriments in patient-reported health-related quality of life, and, for most parts of the world, at least one of the additional therapies (docetaxel) is relatively inexpensive and has a short duration of treatment. Systemic management of hormone-sensitive prostate cancer has taken a giant leap forward for the first time in seven decades.

It would seem that all that remains is to decide which treatment to add to testosterone suppression. This choice is mainly dictated by availability and reimbursement. Some patients may be too frail or have comorbidities that mean that one or another of the available additional therapies may not be suitable for them; for those men, testosterone suppression alone may still be the best option. Such a situation might reasonably be expected to be uncommon, and certainly all guidelines advocate for the addition of one of the proven agents to testosterone suppression where clinically appropriate (11-14).

In this issue of the Journal, Wallis et al. (15) describe a situation similar to the imaginary one at the start of this editorial but taken a half-step further, analogous to the spacesuited leg waving just above the lunar dust. They report evidence from the Canadian province of Ontario indicating that the clinical community has failed to take the necessary small step. This study shows that of 3556 patients with synchronous, metastatic, hormone-sensitive prostate cancer commencing testosterone suppression in the 5 years after the CHAARTED data were presented, 78.6% were offered no additional treatment. Only about 11% received docetaxel, and a small proportion (1.5%) were infered to have received abiraterone acetate plus prednisone. The survival of patients in this study was found to be lower than in the relevant clinical trials. The survival outcome is probably to be expected because the reported population was older overall (only those older than 65 years of age were included) and otherwise may not be the same as those included in clinical trials, although the reported Charlson comorbidity index mean scores were low.

Canada is not alone in this pattern of care and the resultant outcomes. Data from the US Veterans Health Administration showed that 62% of patients received testosterone suppression only (16). Another US study showed that 65% of patients did not receive an agent shown to improve survival in addition to testosterone suppression (17). My own country of Australia, which I would like to think is forward thinking and in favor of evidence-based treatment, unfortunately showed similar results: Only 33% of patients had docetaxel added to their treatment in 2018, although the figure was higher (64%) in patients...
under the age of 70 years (18). The other agents are not yet reim-
bursed in Australia for this indication.

What could be the explanation? It cannot be lack of aware-
ness. The CHAARTED and STAMPEDE data for the addition of
docetaxel were promoted widely. Wallis et al. (15) show that
prescriptions of abiraterone increased slightly after the
LATITUDE data were presented, but docetaxel prescriptions
decreased and against expectations that an even higher propor-
tion of patients overall received testosterone suppression alone.
Cost and other factors affecting access might be potential con-
siderations. Access to some of the therapies was and still is lim-
ited in many countries, but docetaxel is inexpensive and readily
available, and it is still recommended even in some resource-
limited countries (13,19). Wallis et al. contend that age affects
the mortality of these patients, which may be true. I would pro-
pose an alternative possible explanation: perhaps age biases the
treatment choices made by clinicians, and older patients some-
times may be disproportionately undertreated.

The problem may run even deeper than that. The TITAN trial
of apalutamide commenced recruitment in late 2015, yet only
11% of participants received docetaxel before commencement
of study therapy (5). Similarly, the ARCHES trial of enzalutamid-
ate commenced recruitment in 2016, yet only 18% of participants
received docetaxel (6). These findings suggest that even those
clinicians engaged in research and generating evidence were
frequently unwilling to use docetaxel in many patients who
were fit to receive it, despite the convincing evidence available
at the time. In contrast, 45% of patients in ENZAMET received
docetaxel concurrently with enzalutamide, with even higher
uptake in the subgroup with high-volume disease (20). Survival
outcomes in the control arm of ENZAMET were similar to those
of the experimental arm of CHAARTED (8). The PEACE-1 trial
(NCT01957436) was amended in 2017 to require docetaxel in the
standard-of-care arms (9), and the ARASENS trial (NCT02799602,
yet to be reported) used docetaxel for all participants. It is en-
couraging to see the evidence now being built into the design
of control arms in pivotal trials.

What conclusions can we draw? We know the data. We can
see the quantitative and qualitative advantages of using these
therapies earlier rather than waiting for castration resistance to
develop. Could it be that oncologists around the world are sim-
ply too entrenched in their ways to alter practice, even when
clear and convincing evidence exists to show that we can do
much better? We have been called to a “cancer moonshot” (21),
but perhaps what we really need is a “groundshot” (22) that
gives uniform access to treatments that are known to work.

Disclosures: IDD is chair of ANZUP Cancer Trials Group and
global co-chair of the ENZAMET trial. Advisory boards within
past 2 years (all honoraria to ANZUP): Astellas, AstraZeneca,
Bayer, Eisai, Ipsen, Janssen, Merck/MSD, Pfizer, Roche. Research
funding (trial funding to Eastern Health or ANZUP): Amgen,
Astellas, AstraZeneca, Bayer, BMS, Eisai, Exelixis, Janssen,
Medivation, Movember, MSD, Pfizer, Roche/Genentech, Seagen.
Company board (unremunerated): ANZUP Cancer Trials Group.

Author contributions: Writing—original draft: IDD. Writing—
reviewing and editing: IDD.

Data Availability
Not applicable.

References
1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in meta-
static hormone-sensitive prostate cancer. N Engl J Med. 2015;373(7):737–746.
2. James ND, Sydes MR, Clarke NW, et al.; STAMPEDE investigators. Addition of
docetaxel, abiraterone, or both to first-line long-term hormone therapy in
prostate cancer (STAMPEDE): survival results from an adaptive, multiarm,
multistage, platform randomised controlled trial. Lancet. 2016;387(10024):
1163–1177.
3. James ND, de Bono JS, Spears MR, et al.; STAMPEDE investigators. Abiraterone
for prostate cancer not previously treated with hormone therapy.
N Engl J Med 2017;377(4):338–351.
4. Fizazi K, Tran N, Fein L, et al.; LATITUDE investigators. Abiraterone plus predni-
solone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;
377(4):352–360.
5. Chi KN, Agarwal N, Bjartell A, et al.; TITAN investigators. Abiraterone for
metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):
13–24.
6. Armstrong AJ, Szmulewicz RW, Petylak DP, et al. ARCHES: a randomized,
phase III study of androgen deprivation therapy with enzalutamide or pla-
cebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol.
2019;37(32):2974–2986.
7. Armstrong AJ, Iguchi T, Azad AA, et al. Final overall survival (OS) analysis from
ARCHES: a phase III, randomized, double-blind, placebo (PBO)-con-
trolled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT)
in men with metastatic hormone-sensitive prostate cancer (mHSPC). Paper
presented at: ESMO Congress 2021 Virtual; September 16-21, 2021. Abstract
LBA25.
8. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line
therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
9. Fizazi K, Carles J, Fenaud S, et al. Phase III trial with a 2x2 factorial design in
men with de novo metastatic castration-sensitive prostate cancer: overall
survival with abiraterone acetate plus prednisone in PEACE-1. Paper pre-
sented at: ESMO Congress 2021 Virtual; September 16-21, 2021. Abstract
LBA44 PR.
10. Attard G, Brown L, Clarke N, et al. Abiraterone acetate plus prednisolone with
or without enzalutamide added to androgen deprivation therapy compared to
ADT alone for men with high-risk nonmetastatic prostate cancer: primary
combined analysis from two comparisons in the STAMPEDE platform proto-
col. Paper presented at: ESMO Congress 2021 Virtual; September 16-21, 2021.
Abstract LBA44 PR.
11. Mottet N, Cornford F, van den Bergh RCN, et al. Prostate cancer. European
Association of Urology. https://uroweb.org/guideline/prostate-cancer/.
Published 2020. Accessed September 7, 2021.
12. Virgo KS, Rumble RB, de Wit R, et al. Initial management of noncastrate ad-
vanced, recurrent, or metastatic prostate cancer: ASCO guideline update.
J Clin Oncol. 2021;39(19):1274–1305.
13. National Comprehensive Cancer Network. Prostate cancer core resources.
Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/pros-
tate_core.pdf. Published August 25, 2021. Accessed September 7, 2021.
14. NHS England interim treatment options during the COVID-19 pandemic.
National Institute for Health and Care Excellence Web site. https://www.
nice.org.uk/guidance/ng161/resources/nhs-england-interim-treatment-
options-during-the-covid-19-pandemic-pdf-8715724381. Accessed September
7, 2021.
15. Wallis CJD, Malone S, Cagianos I, et al. Real-world utilization of androgen
depression therapy-intensification among older Canadian men with de
 novo metastatic prostate cancer. JNCI Cancer Spectrum. 2021. doi:
10.1093/jncics/pkab082.
16. Tagawa ST, Sandin R, Sah J, Mu Q, Freedland SJ. 67P Treatment patterns of
metastatic castration-sensitive prostate cancer (mCSPC): a real-world evi-
dence study. Ann Oncol. 2020;31(S5):S41–S54.
17. George DJ, Agarwal N, Rider JR, et al. Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. J Clin Oncol. 2021;39(15 Suppl):5074–5074.

18. Azad AA, Tran B, Davis ID, et al. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer [published online ahead of print March 12, 2021]. Intern Med J. 2021. doi: 10.1111/imj.15288.

19. Chiong E, Murphy DG, Akaza H, et al.; ANZUP Cancer Trials Group. Management of patients with advanced prostate cancer in the Asia Pacific region: “real-world” consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU Int. 2019;123(1):22–34.

20. Sweeney CJ, Martin AJ, Stockler MR, et al.; ENZAMET Trial Investigators and the Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur Urol. 2021;80(3):275–279.

21. Agus DB, Jaffee EM, Van Dang C. Cancer moonshot 2.0. Lancet Oncol. 2021;22(2):164–165.

22. Gyawali B, Sullivan R, Booth CM. Cancer groundshot: going global before going to the moon. Lancet Oncol. 2018;19(3):288–290.